The Centers for Medicare & Medicaid Services (CMS) runs the Medicare Drug Price Negotiation Program to negotiate maximum fair prices for certain high expenditure, single source drugs and biological products. CMS describes the maximum fair price, or MFP, as the negotiated price for a selected drug for a given year that is updated for inflation when applicable. Under the law, CMS selects drugs, negotiates or renegotiates their MFPs with participating manufacturers, publishes agreed prices, and oversees compliance, according to CMS.

What the program does

CMS states that sections 11001 and 11002 of the Inflation Reduction Act establish the program to negotiate MFPs for certain high expenditure, single source drugs and biological products. In each initial price applicability year, CMS will publish a list of selected drugs for negotiation and, if applicable, renegotiation; enter into agreements with manufacturers that choose to participate; negotiate or renegotiate MFPs; publish any agreed MFPs; and carry out administrative and compliance duties, including civil monetary penalties when applicable, according to CMS. CMS explains that the MFP for a selected drug is negotiated in accordance with the Social Security Act and, when applicable, updated to account for inflation.

How CMS selects drugs

For initial price applicability year 2029 and each subsequent year, CMS will select up to 20 drugs covered under Medicare Part D and/or payable under Part B for negotiation, according to CMS. CMS codifies policies governing publication of the selected drug list, identification of selected drugs, ranking of negotiation‑eligible drugs, and identification of qualifying single source drugs, consistent with statute and prior guidance. CMS also clarifies how it will identify qualifying single source drugs when specific new formulations present program integrity concerns, including certain fixed combination drugs, according to CMS.

A potential qualifying single source drug is not eligible for selection, and a selected drug will cease to be a selected drug, if CMS determines that the Food and Drug Administration has approved a generic or licensed a biosimilar to the product included in the potential or selected drug and that the generic or biosimilar is marketed, CMS says. CMS codifies how it will determine when such generic or biosimilar marketing meets “Bona Fide Marketing” and sets the criteria, process, and timing for determinations of ineligibility or deselection, and for monitoring continued marketing status, according to CMS. CMS lists drugs with deselection determinations and the timing of their removal from the selected drug list, and issues memos through the CMS Health Plan Management System to notify affected plans and stakeholders, according to CMS.

Manufacturer agreements and required data

Section 1193(a) of the Social Security Act establishes a Negotiation Program Agreement. CMS states that a willing primary manufacturer of a selected drug must enter into and sign this agreement by Feb. 28 after the date the selected drug list is published. CMS codifies the timing and process for executing and terminating the agreement and the requirements a willing primary manufacturer must follow after execution, including mandatory submission of data to CMS, consistent with statute and prior guidance.

After entering an agreement, the primary manufacturer must submit information on the non‑Federal Average Manufacturer Price (non‑FAMP) and any information CMS requires to carry out the program, including information related to manufacturer‑specific factors listed in section 1194(e)(1) of the Act, according to CMS. CMS states that primary manufacturers, as well as other interested parties, may choose to provide evidence about selected drugs and possible therapeutic alternatives under section 1194(e)(2). CMS codifies submission requirements, update requirements for submitted data, and how it will consider evidence from comparative effectiveness studies.

How negotiation works

CMS develops and uses a consistent methodology and process for reaching agreement on “the lowest [MFP] for each selected drug” in accordance with section 1194(b)(1) of the Act. The process includes engagement with primary manufacturers and interested parties, including patients; CMS’s written initial offer with a concise justification; the manufacturer’s ability to accept the offer or submit a statutory written counteroffer; optional negotiation meetings; additional price exchanges; a conclusion of negotiation, including a final offer from CMS where applicable; and the publication of agreed MFPs and explanations, according to CMS. CMS codifies these procedures, including the exchange of offers and counteroffers, and how the MFP is published and explained.

CMS also codifies policies for renegotiation. Section 1194(f) of the Act governs identification of renegotiation‑eligible drugs, selection for renegotiation, and the renegotiation process. CMS states it will use criteria for determining renegotiation eligibility and selection, the types of information it will consider, opportunities and requirements for data submission, and a process that remains consistent, to the extent practicable, with the negotiation process and methodology. For initial price applicability year 2029 and beyond, CMS will consider the agreed‑upon MFP for a drug selected for renegotiation as part of its consideration of section 1194(e)(1) factors, according to CMS.

Publishing and updating negotiated prices

CMS publishes selected drugs and negotiated prices in a public file. CMS states that the file contains the list of National Drug Codes (NDCs) associated with each selected drug for which any negotiated MFP would apply consistent with guidance. For drugs with agreed negotiated prices, the file includes the single negotiated price for a 30‑day equivalent supply, the NDC‑9 per unit price, and the NDC‑11 per package price, along with information on updates to NDCs and MFPs, according to CMS.

CMS explains that the file is updated at least annually each year after the first initial price applicability year in the drug’s price applicability period to show the inflation‑adjusted negotiated price. CMS also makes recurring updates to reflect application of the negotiated price to new NDC‑11s, removal of the negotiated price from NDC‑11s when appropriate, and when a drug is no longer selected, according to CMS. CMS publishes the file in .xlsx and .csv formats.

How prices apply in Medicare and on formularies

CMS states that section 11001(b) of the Inflation Reduction Act added that, for selected drugs during a price applicability period, payment may not be based on an amount above the MFP plus any dispensing fees. CMS also codifies the Medicare Part D formulary inclusion requirement. According to CMS, section 1860D‑4(b)(3)(I)(i) requires that, beginning in 2026 and for each year thereafter, Part D formularies must include each covered Part D drug that is a selected drug when an MFP is in effect for that year. CMS notes that this does not prevent a Part D plan sponsor from removing a selected drug from a formulary if such removal is allowed under the specified successor regulation.

Program integrity and special provisions

To address a program integrity risk involving fixed combination drugs, CMS finalizes a policy for identifying qualifying single source drugs when a manufacturer markets a new formulation that adds an active component enabling an alternative route of administration. Under this policy, when certain conditions are met, CMS will group all dosage forms and strengths of products with the shared active components and the same NDA/BLA holder to identify the potential qualifying single source drug, according to CMS. CMS provides an example to illustrate how products may be aggregated under this policy.

CMS also implements provisions for a Temporary Floor for Small Biotech Drugs. CMS explains that while the exception for small biotech drugs from consideration as negotiation‑eligible applied to initial price applicability years 2026 through 2028, the definition of a “Small Biotech Drug” applies to determining eligibility for a temporary floor that limits CMS from offering or agreeing to a counteroffer below that floor for selected drugs that qualify. CMS states this temporary floor applies for initial price applicability years 2029 and 2030 and includes a modification to the treatment of non‑FAMP in the adjusted ceiling calculation for certain qualifying drugs.